Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Safety and Efficacy Studies, Pharmacy Education, and the NASEM Report on Compounded Topical Pain Creams

Author(s):  Allen Loyd V Jr

Issue:  Sep/Oct 2020 - Volume 24, Number 5
View All Articles in Issue

Page(s):  356

Safety and Efficacy Studies, Pharmacy Education, and the NASEM Report on Compounded Topical Pain Creams Page 1

Download in electronic PDF format for $75

Abstract:  

Related Keywords: Loyd V. Allen, Jr., PhD, RPh, National Academies of Sciences Engineering Medicine, NASEM Report, drug safety, drug efficacy, compounding formulations, pharmacy education, clinical pharmacy, pharmacy curriculum

Related Categories: LEGAL, QUALITY CONTROL, PHARMACY EDUCATION, PROFESSIONAL ISSUES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Safety and Efficacy Studies, Pharmacy Education, and the NASEM Report on Compounded Topical Pain Creams
Allen Loyd V Jr
Sep/Oct 2020
Pg. 356

NASEM Report on Compounded Topical Pain Creams
Allen Loyd V Jr
Nov/Dec 2020
Pg. 446-448

PreScription: The NASEM cBHT Report, Part 1
Allen Loyd V Jr
Nov/Dec 2020
Pg. 444

PreScription: The NASEM cBHT Report, Part 2
Allen Loyd V Jr
Jan/Feb 2021
Pg. 4

Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety
Allen W Chris
, Greeson Nicole MH, Mixon William
Nov/Dec 2020
Pg. 451-458

Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
Jul/Aug 2004
Pg. 269-274

Efficacy and Tolerability of Compounded Bioidentical Hormone Replacement Therapy
Vigesaa Kristy A
, Downhour Nathan P, Chui Michelle A, Cappellini Linda, Musil John D, McCallian Dennis J
Jul/Aug 2004
Pg. 313-319

Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
Nov/Dec 2003
Pg. 449-450

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

FDA-funded Report on Compounded Hormones is Tainted, Analysis Shows
Brunner Scott
May/Jun 2021
Pg. 206-209

In Vitro Permeability, Irritability, and Release Evaluation of Commonly Used Topical Diclofenac Gel Preparations (1%, 5%, and 10%)
Kohan Hamed Gilzad
, Baker David M, Sani Shabnam, Bielecki-Wilken Kathleen A, Ramirez Alfonso
Mar/Apr 2021
Pg. 146-155

Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M
, Rivera Gerard, Balthasar Jan, Florea Naomi
Jul/Aug 2015
Pg. 295-300

Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M
, Rivera Gerard, Balthasar Jan, Florea Naomi
Mar/Apr 2024
Pg. 111-116

The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013
Lutz Eugene
, Pauletti Giovanni, Carvalho Maria, Davidson Gigi, Ashworth Lisa, Subramaniam Vaiyapuri, Llambí Francesc
Jan/Feb 2014
Pg. 6-12

Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
Jul/Aug 2020
Pg. 296-297

PreScription: The Past (-->2020), The Present, and The Future (2021-->)
Allen Loyd V Jr
Mar/Apr 2021
Pg. 92

Compounding Enclosures: Ensuring Safety During the Preparation of Sterile and Nonsterile Formulations
Ashe Krystina
, Baskett Dustin
Sep/Oct 2018
Pg. 387-398

Auditing Safety of Compounding and Reconstituting of Intravenous Medicines on Hospital Wards in Finland
Suvikas-Peltonen Eeva
, Palmgren Joni, Häggman Verner, Celikkayalar Ercan, Manninen Raija, Airaksinen Marja
Nov/Dec 2017
Pg. 518-529

Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance
Greeson Nicole MH
, Mixon William, Allan W Chris
Sep/Oct 2020
Pg. 371-379

FDAMA Proposed List of Agents Not to be Compounded due to Withdrawal for Safety/Efficacy Concerns
Allen Loyd V Jr
Jan/Feb 1999
Pg. 25-29

Return to Top